首頁 > 市場調查報告書 > 製藥

糖尿病

市場調查報告書

商品編碼

1606457

糖尿病視網膜病變治療市場，按糖尿病視網膜病變類型、治療類型、最終用戶、國家和地區 - 2024-2032 年行業分析、市場規模、市場佔有率和預測

Diabetic Retinopathy Therapeutic Market, By Diabetic Retinopathy Type, By Treatment Type, By End User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

出版日期: 2024年11月04日 | 出版商:

AnalystView Market Insights | 英文 303 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

報告要點

2023年，糖尿病視網膜病變治療市場規模為91.0932億美元，2024年至2032年複合年成長率為6.88%。

糖尿病視網膜病變治療市場-市場動態

糖尿病和糖尿病視網膜病變盛行率不斷上升，推動市場需求

全球糖尿病發生率不斷上升，導致越來越多的人罹患糖尿病視網膜病變。據美國疾病管制與預防中心 (CDC) 稱，到 2021 年，美國各年齡層估計有 960 萬人患有糖尿病視網膜病變。然而，治療方案的複雜性和治療的潛在副作用可能會阻礙患者堅持治療按照他們規定的治療計劃。相反，糖尿病視網膜病變治療方面正在進行的研究和技術進步預計將促進市場成長。此外，人們對糖尿病患者定期眼科檢查重要性的認知不斷提高，為糖尿病視網膜病變治療市場的成長提供了機會。

糖尿病視網膜病變治療市場 - 關鍵見解

根據我們的研究分析師分享的分析，預計全球市場在預測期內（2024-2032 年）每年將以 6.88% 左右的複合年成長率成長

根據糖尿病視網膜病變類型細分，預計非增殖性糖尿病視網膜病變將在 2023 年顯示最大的市場佔有率

根據治療類型細分，抗血管內皮生長因子（VGEF）藥物是2023年的主導細分市場

按地區分類，北美糖尿病視網膜病變治療市場是 2023 年主要的收入來源

糖尿病視網膜病變治療市場-細分分析：

全球糖尿病視網膜病變治療市場根據糖尿病視網膜病變類型、治療類型、最終用戶和地區進行細分。

根據糖尿病視網膜病變類型，市場分為兩類：增殖性糖尿病視網膜病變和非增殖性糖尿病視網膜病變。非增殖性糖尿病視網膜病變領域主導市場。這主要是由於糖尿病患者的盛行率較高，以及人們對早期檢測和治療方案的認知和可用性不斷提高。

根據最終用戶，市場分為四大類：眼科中心、醫院、門診手術中心等。醫院產業在市場中佔據主導地位，並可能在預測期內保持其主導地位。這種主導地位主要是由醫院提供全面護理的能力推動的，包括先進的診斷工具和手術干預，這對於有效管理糖尿病視網膜病變至關重要。

糖尿病視網膜病變治療市場 - 地理洞察

從地理來看，該市場廣泛分佈於北美、拉丁美洲、歐洲、亞太、中東和非洲等地區。這些區域根據開展業務的國家進一步分類。

糖尿病視網膜病變治療市場-競爭格局：

糖尿病視網膜病變盛行率的不斷上升正在推動競爭格局的發展，其特點是創新的治療策略和對全面患者護理的關注。該公司正在利用遠距醫療和數位健康解決方案等先進技術來增強患者參與度並改善獲得護理的機會。此外，許多組織正在優先考慮研究和開發，以推出針對糖尿病視網膜病變不同階段的新療法，從而解決未滿足的醫療需求。與醫療保健提供者和研究機構的合作和夥伴關係也是常見策略，使公司能夠擴大市場範圍並改善治療結果。

市場片段
- 以糖尿病視網膜病變類型分類的糖尿病視網膜病變治療市場片段
- 按治療類型分類的糖尿病視網膜病變治療市場片段
- 最終使用者的糖尿病視網膜病變治療市場片段
- 按國家/地區分類的糖尿病視網膜病變治療市場片段
- 按地區分類的糖尿病視網膜病變治療市場片段
競爭洞察

第 3 章：糖尿病視網膜病變治療的主要市場趨勢

糖尿病視網膜病變治療市場促進因素
- 市場促進因素的影響分析
糖尿病視網膜病變治療市場限制
- 市場限制影響分析
糖尿病視網膜病變治療市場機會
糖尿病視網膜病變治療市場未來趨勢

第 4 章：糖尿病視網膜病變治療產業研究

PEST分析
波特五力分析
成長前景圖
規範架構分析

第 5 章：糖尿病視網膜病變治療市場：地緣政治緊張局勢升級的影響

COVID-19 大流行的影響
俄羅斯-烏克蘭戰爭的影響
中東衝突的影響

第 6 章：糖尿病視網膜病變治療市場格局

2023 年糖尿病視網膜病變治療市佔分析
按主要製造商分類的故障數據
- 既有參與者分析
- 新興參與者分析

第 7 章：糖尿病視網膜病變治療市場 - 依糖尿病視網膜病變類型

概述
- 按糖尿病視網膜病變類型分類的細分市場佔有率分析
- 增殖性糖尿病視網膜病變
- 非增殖性糖尿病視網膜病變

第 8 章：糖尿病視網膜病變治療市場 - 依治療類型

概述
- 按治療類型分類的細分市場佔有率分析
- 雷射手術
- 抗血管內皮生長因子（VEGF）藥物
- 眼內類固醇注射
- 玻璃體切除術

第 9 章：糖尿病視網膜病變治療市場 - 依最終用戶

概述
- 按最終用戶分類的細分市場佔有率分析
- 眼科中心
- 醫院
- 門診手術中心
- 其他

第 10 章：糖尿病視網膜病變治療市場 - 按地理位置

介紹
- 按地理位置分類的細分市場佔有率分析
北美洲
- 概述
- 北美糖尿病視網膜病變治療主要製造商
- 北美市場規模和預測（按國家）
- 北美市場規模與預測（按糖尿病視網膜病變類型）
- 北美市場規模和預測（按治療類型）
- 北美市場規模和預測（按最終用戶）
- 美國
- 加拿大
歐洲
- 概述
- 歐洲糖尿病視網膜病變治療主要製造商
- 歐洲市場規模和預測（按國家）
- 歐洲市場規模與預測（按糖尿病視網膜病變類型）
- 歐洲市場規模和預測（按治療類型）
- 歐洲市場規模和預測（按最終用戶）
- 德國
- 義大利
- 英國
- 法國
- 俄羅斯
- 荷蘭
- 瑞典
- 波蘭
- 歐洲其他地區
亞太地區 (APAC)
- 概述
- 亞太地區糖尿病視網膜病變治療主要製造商
- 亞太地區市場規模與預測（按國家）
- 亞太地區市場規模與預測（依糖尿病視網膜病變類型）
- 亞太地區市場規模與預測（按治療類型）
- 亞太地區市場規模和預測（按最終用戶）
- 印度
- 中國
- 日本
- 韓國
- 澳洲
- 泰國
- 印尼
- 菲律賓
- 亞太地區其他地區
拉丁美洲
- 概述
- 拉丁美洲糖尿病視網膜病變治療主要製造商
- 拉丁美洲市場規模與預測（按國家）
- 拉丁美洲市場規模與預測（按糖尿病視網膜病變類型）
- 拉丁美洲市場規模與預測（按治療類型）
- 拉丁美洲市場規模和預測（按最終用戶）
- 巴西
- 墨西哥
- 阿根廷
- 哥倫比亞
- 拉丁美洲其他地區
中東和非洲
- 概述
- 中東和非洲糖尿病視網膜病變治療主要製造商
- 中東和非洲市場規模及預測（按國家）
- 中東和非洲市場規模及預測（依糖尿病視網膜病變類型）
- 中東和非洲市場規模及預測（按治療類型）
- 中東和非洲市場規模及預測（按最終用戶）
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 以色列
- 土耳其
- 阿爾及利亞
- 埃及
- MEA 的其餘部分

第 11 章：主要供應商分析 - 糖尿病視網膜病變治療產業

競爭儀表板
- Competitive Benchmarking
- Competitive Positioning
公司簡介
- F. Hoffmann-La Roche Ltd.
- Abbott
- Alimera Sciences
- Novartis AG
- Pfizer Inc.
- Regeneron Pharmaceuticals, Inc.
- Bayer AG
- Oxurion NV
- ABBVIE INC.
- Sirnaomics
- Ampio Pharmaceuticals Inc.
- BCNPeptides
- Genentech, Inc.
- Kowa Company Ltd.
- Aurobindo Pharma
- Bausch Health Companies Inc.
- Accord Healthcare
- Regeneron Pharmaceuticals Inc.
- Lumenis Be Ltd.
- Glycadia, Inc.
- Others

第 12 章：360 度分析師視角

第 13 章：附錄

研究方法
參考
縮寫
免責聲明
聯絡我們

簡介目錄

Product Code: ANV4172

REPORT HIGHLIGHT

Diabetic retinopathy therapeutic market size was valued at USD 9,109.32 Million in 2023, expanding at a CAGR of 6.88% from 2024 to 2032.

Diabetic retinopathy is a serious eye condition stemming from complications related to diabetes mellitus and is a leading cause of blindness worldwide. The severity of diabetic retinopathy depends on several factors, including the type of diabetes, the duration of the disease, and how well blood sugar levels are managed. Early symptoms may be minimal or even absent, but as the condition progresses, individuals can experience blurred vision, fluctuating eyesight, and impaired color perception, potentially leading to blindness if not addressed.

Diabetic Retinopathy Therapeutic Market- Market Dynamics

Increasing prevalence of diabetes and diabetic retinopathy to propel market demand

The rising incidence of diabetes globally has led to a higher number of individuals developing diabetic retinopathy. According to Centers for Disease Control and Prevention (CDC), an estimated 9.6 million people across all ages in the US were living with diabetic retinopathy in 2021.However, the complexity of treatment regimens and the potential side effects of therapies can discourage patients from adhering to their prescribed treatment plans. On the contrary, ongoing research and technological advancements in the management of diabetic retinopathy are expected to boost market growth. Furthermore, Increased awareness about the importance of regular eye examinations for diabetes patients presents an opportunity for growth in the diabetic retinopathy therapeutic market.

Diabetic Retinopathy Therapeutic Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 6.88% over the forecast period (2024-2032)

Based on diabetic retinopathy type segmentation, non-proliferative diabetic retinopathy was predicted to show maximum market share in the year 2023

Based on treatment type segmentation, anti-vascular endothelial growth factor (VGEF) drug was the leading segment in 2023

On the basis of region, The North America diabetic retinopathy therapeutic market was the leading revenue generator in 2023

Diabetic Retinopathy Therapeutic Market- Segmentation Analysis:

The Global Diabetic Retinopathy Therapeutic Market is segmented on the basis of Diabetic Retinopathy Type, Treatment Type, End user, and Region.

The market is divided into two categories based on diabetic retinopathy type: proliferative diabetic retinopathy and non-proliferative diabetic retinopathy. The non-proliferative diabetic retinopathy sector dominates the market. This is mainly due to its higher prevalence among diabetic patients and the increasing awareness and availability of early detection and treatment options.

The market is divided into four categories based on end user: ophthalmic centers, hospitals, ambulatory surgery centers, and others. The hospitals sector dominates the market and is likely to maintain its dominance during the forecast period. This dominance is primarily driven by hospitals' ability to provide comprehensive care, including advanced diagnostic tools and surgical interventions, which are crucial for managing diabetic retinopathy effectively.

Diabetic Retinopathy Therapeutic Market- Geographical Insights

Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.

Diabetic Retinopathy Therapeutic Market- Competitive Landscape:

The increasing prevalence of diabetic retinopathy is driving a competitive landscape characterized by innovative treatment strategies and a focus on comprehensive patient care. Companies are leveraging advanced technologies, such as telemedicine and digital health solutions, to enhance patient engagement and improve access to care. Additionally, many organizations are prioritizing research and development to introduce novel therapies that target various stages of diabetic retinopathy, thereby addressing unmet medical needs. Collaboration and partnerships with healthcare providers and research institutions are also common strategies, enabling companies to expand their market reach and improve treatment outcomes.

Recent Developments:

In April 2024, Ocular Therapeutix, Inc. announced promising topline results from its Phase 1 HELIOS study, which investigated AXPAXLI against a sham control in patients with moderately severe to severe non-proliferative diabetic retinopathy (NPDR) without diabetic macular edema (DME). The study's positive findings highlight Ocular's commitment to developing innovative therapies for conditions like wet age-related macular degeneration and diabetic retinopathy.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL DIABETIC RETINOPATHY THERAPEUTIC MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

F. Hoffmann-La Roche Ltd.
Abbott
Alimera Sciences
Novartis AG
Pfizer Inc.
Regeneron Pharmaceuticals, Inc.
Bayer AG
Oxurion NV
ABBVIE INC.
Sirnaomics
Ampio Pharmaceuticals Inc.
BCNPeptides
Genentech, Inc.
Kowa Company Ltd.
Aurobindo Pharma
Bausch Health Companies Inc.
Accord Healthcare
Regeneron Pharmaceuticals Inc.
Lumenis Be Ltd.
Glycadia, Inc.
Others

GLOBAL DIABETIC RETINOPATHY THERAPEUTIC MARKET, BY DIABETIC RETINOPATHY TYPE- MARKET ANALYSIS, 2019 - 2032

Proliferative Diabetic Retinopathy
Non-proliferative Diabetic Retinopathy

GLOBAL DIABETIC RETINOPATHY THERAPEUTIC MARKET, BY TREATMENT TYPE- MARKET ANALYSIS, 2019 - 2032

Laser Surgery
Anti-vascular Endothelial Growth Factor (VEGF) Drug
Intraocular Steroid Injection
Vitrectomy

GLOBAL DIABETIC RETINOPATHY THERAPEUTIC MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032

Ophthalmic Centers
Hospitals
Ambulatory Surgery Centers
Others

GLOBAL DIABETIC RETINOPATHY THERAPEUTIC MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
The U.S.
Canada
Europe
Germany
France
Italy
Spain
United Kingdom
Russia
Netherlands
Sweden
Poland
Rest of Europe
Asia Pacific
India
China
South Korea
Japan
Australia
Thailand
Indonesia
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
United Arab Emirates
Israel
Turkey
Algeria
Egypt
Rest of MEA

1. Diabetic Retinopathy Therapeutic Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. Diabetic Retinopathy Therapeutic Market Snippet by Diabetic Retinopathy Type
- 2.1.2. Diabetic Retinopathy Therapeutic Market Snippet by Treatment Type
- 2.1.3. Diabetic Retinopathy Therapeutic Market Snippet by End User
- 2.1.4. Diabetic Retinopathy Therapeutic Market Snippet by Country
- 2.1.5. Diabetic Retinopathy Therapeutic Market Snippet by Region
2.2. Competitive Insights

3. Diabetic Retinopathy Therapeutic Key Market Trends

3.1. Diabetic Retinopathy Therapeutic Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Diabetic Retinopathy Therapeutic Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Diabetic Retinopathy Therapeutic Market Opportunities
3.4. Diabetic Retinopathy Therapeutic Market Future Trends

4. Diabetic Retinopathy Therapeutic Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Diabetic Retinopathy Therapeutic Market: Impact of Escalating Geopolitical Tensions

5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts

6. Diabetic Retinopathy Therapeutic Market Landscape

6.1. Diabetic Retinopathy Therapeutic Market Share Analysis, 2023
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Diabetic Retinopathy Therapeutic Market - By Diabetic Retinopathy Type

7.1. Overview
- 7.1.1. Segment Share Analysis, By Diabetic Retinopathy Type, 2023 & 2032 (%)
- 7.1.2. Proliferative Diabetic Retinopathy
- 7.1.3. Non-proliferative Diabetic Retinopathy

8. Diabetic Retinopathy Therapeutic Market - By Treatment Type

8.1. Overview
- 8.1.1. Segment Share Analysis, By Treatment Type, 2023 & 2032 (%)
- 8.1.2. Laser Surgery
- 8.1.3. Anti-vascular Endothelial Growth Factor (VEGF) Drug
- 8.1.4. Intraocular Steroid Injection
- 8.1.5. Vitrectomy

9. Diabetic Retinopathy Therapeutic Market - By End User

9.1. Overview
- 9.1.1. Segment Share Analysis, By End User, 2023 & 2032 (%)
- 9.1.2. Ophthalmic Centers
- 9.1.3. Hospitals
- 9.1.4. Ambulatory Surgery Centers
- 9.1.5. Others

10. Diabetic Retinopathy Therapeutic Market- By Geography

10.1. Introduction
- 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
10.2. North America
- 10.2.1. Overview
- 10.2.2. Diabetic Retinopathy Therapeutic Key Manufacturers in North America
- 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.2.4. North America Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
- 10.2.5. North America Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
- 10.2.6. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.2.7. U.S.
  - 10.2.7.1. Overview
  - 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.2.7.3. U.S. Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
  - 10.2.7.4. U.S. Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.2.7.5. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.2.8. Canada
  - 10.2.8.1. Overview
  - 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.2.8.3. Canada Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
  - 10.2.8.4. Canada Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.2.8.5. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.3. Europe
- 10.3.1. Overview
- 10.3.2. Diabetic Retinopathy Therapeutic Key Manufacturers in Europe
- 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.3.4. Europe Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
- 10.3.5. Europe Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
- 10.3.6. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.3.7. Germany
  - 10.3.7.1. Overview
  - 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.7.3. Germany Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
  - 10.3.7.4. Germany Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.3.7.5. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.3.8. Italy
  - 10.3.8.1. Overview
  - 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.8.3. Italy Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
  - 10.3.8.4. Italy Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.3.8.5. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.3.9. United Kingdom
  - 10.3.9.1. Overview
  - 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.9.3. United Kingdom Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
  - 10.3.9.4. United Kingdom Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.3.9.5. United Kingdom Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.3.10. France
  - 10.3.10.1. Overview
  - 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.10.3. France Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
  - 10.3.10.4. France Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.3.10.5. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.3.11. Russia
  - 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.11.2. Russia Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
  - 10.3.11.3. Russia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.3.11.4. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.3.12. Netherlands
  - 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.12.2. Netherlands Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
  - 10.3.12.3. Netherlands Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.3.12.4. Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.3.13. Sweden
  - 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.13.2. Sweden Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
  - 10.3.13.3. Sweden Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.3.13.4. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.3.14. Poland
  - 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.14.2. Poland Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
  - 10.3.14.3. Poland Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.3.14.4. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.3.15. Rest of Europe
  - 10.3.15.1. Overview
  - 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.15.3. Rest of the Europe Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
  - 10.3.15.4. Rest of the Europe Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.3.15.5. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.4. Asia Pacific (APAC)
- 10.4.1. Overview
- 10.4.2. Diabetic Retinopathy Therapeutic Key Manufacturers in Asia Pacific
- 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.4.4. Asia Pacific Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
- 10.4.5. Asia Pacific Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
- 10.4.6. Asia Pacific Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.4.7. India
  - 10.4.7.1. Overview
  - 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.7.3. India Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
  - 10.4.7.4. India Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.4.7.5. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.4.8. China
  - 10.4.8.1. Overview
  - 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.8.3. China Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
  - 10.4.8.4. China Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.4.8.5. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.4.9. Japan
  - 10.4.9.1. Overview
  - 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.9.3. Japan Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
  - 10.4.9.4. Japan Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.4.9.5. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.4.10. South Korea
  - 10.4.10.1. Overview
  - 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.10.3. South Korea Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
  - 10.4.10.4. South Korea Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.4.10.5. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.4.11. Australia
  - 10.4.11.1. Overview
  - 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.11.3. Australia Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
  - 10.4.11.4. Australia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.4.11.5. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.4.12. Thailand
  - 10.4.12.1. Overview
  - 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.12.3. Thailand Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
  - 10.4.12.4. Thailand Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.4.12.5. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.4.13. Indonesia
  - 10.4.13.1. Overview
  - 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.13.3. Indonesia Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
  - 10.4.13.4. Indonesia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.4.13.5. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.4.14. Philippines
  - 10.4.14.1. Overview
  - 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.14.3. Philippines Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
  - 10.4.14.4. Philippines Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.4.14.5. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.4.15. Rest of APAC
  - 10.4.15.1. Overview
  - 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.15.3. Rest of APAC Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
  - 10.4.15.4. Rest of APAC Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.4.15.5. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.5. Latin America
- 10.5.1. Overview
- 10.5.2. Diabetic Retinopathy Therapeutic Key Manufacturers in Latin America
- 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.5.4. Latin America Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
- 10.5.5. Latin America Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
- 10.5.6. Latin America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.5.7. Brazil
  - 10.5.7.1. Overview
  - 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.7.3. Brazil Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
  - 10.5.7.4. Brazil Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.5.7.5. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.5.8. Mexico
  - 10.5.8.1. Overview
  - 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.8.3. Mexico Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
  - 10.5.8.4. Mexico Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.5.8.5. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.5.9. Argentina
  - 10.5.9.1. Overview
  - 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.9.3. Argentina Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
  - 10.5.9.4. Argentina Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.5.9.5. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.5.10. Colombia
  - 10.5.10.1. Overview
  - 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.10.3. Colombia Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
  - 10.5.10.4. Colombia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.5.10.5. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.5.11. Rest of LATAM
  - 10.5.11.1. Overview
  - 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.11.3. Rest of LATAM Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
  - 10.5.11.4. Rest of LATAM Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.5.11.5. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.6. Middle East and Africa
- 10.6.1. Overview
- 10.6.2. Diabetic Retinopathy Therapeutic Key Manufacturers in Middle East and Africa
- 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.6.4. Middle East and Africa Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
- 10.6.5. Middle East and Africa Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
- 10.6.6. Middle East and Africa Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.6.7. Saudi Arabia
  - 10.6.7.1. Overview
  - 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.7.3. Saudi Arabia Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
  - 10.6.7.4. Saudi Arabia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.6.7.5. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.6.8. United Arab Emirates
  - 10.6.8.1. Overview
  - 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.8.3. United Arab Emirates Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
  - 10.6.8.4. United Arab Emirates Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.6.8.5. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.6.9. Israel
  - 10.6.9.1. Overview
  - 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.9.3. Israel Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
  - 10.6.9.4. Israel Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.6.9.5. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.6.10. Turkey
  - 10.6.10.1. Overview
  - 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.10.3. Turkey Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
  - 10.6.10.4. Turkey Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.6.10.5. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.6.11. Algeria
  - 10.6.11.1. Overview
  - 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.11.3. Algeria Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
  - 10.6.11.4. Algeria Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.6.11.5. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.6.12. Egypt
  - 10.6.12.1. Overview
  - 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.12.3. Egypt Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
  - 10.6.12.4. Egypt Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.6.12.5. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.6.13. Rest of MEA
  - 10.6.13.1. Overview
  - 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.13.3. Rest of MEA Market Size and Forecast, By Diabetic Retinopathy Type, 2019 - 2032 (US$ Million)
  - 10.6.13.4. Rest of MEA Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.6.13.5. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Diabetic Retinopathy Therapeutic Industry

11.1. Competitive Dashboard
- 11.1.1. Competitive Benchmarking
- 11.1.2. Competitive Positioning
11.2. Company Profiles
- 11.2.1. F. Hoffmann-La Roche Ltd.
- 11.2.2. Abbott
- 11.2.3. Alimera Sciences
- 11.2.4. Novartis AG
- 11.2.5. Pfizer Inc.
- 11.2.6. Regeneron Pharmaceuticals, Inc.
- 11.2.7. Bayer AG
- 11.2.8. Oxurion NV
- 11.2.9. ABBVIE INC.
- 11.2.10. Sirnaomics
- 11.2.11. Ampio Pharmaceuticals Inc.
- 11.2.12. BCNPeptides
- 11.2.13. Genentech, Inc.
- 11.2.14. Kowa Company Ltd.
- 11.2.15. Aurobindo Pharma
- 11.2.16. Bausch Health Companies Inc.
- 11.2.17. Accord Healthcare
- 11.2.18. Regeneron Pharmaceuticals Inc.
- 11.2.19. Lumenis Be Ltd.
- 11.2.20. Glycadia, Inc.
- 11.2.21. Others